-Author name in bold denotes the presenting author
-Asterisk * with author name denotes a Non-ASH member
Clinically Relevant Abstract denotes an abstract that is clinically relevant.

PhD Trainee denotes that this is a recommended PHD Trainee Session.

Ticketed Session denotes that this is a ticketed session.

966 Differences in Clinical Course and Management of Sars-CoV2 Infection in Patients with Chronic Lymphocytic Leukemia between the Sequential Pandemic Phases: An Eric Study

Program: Oral and Poster Abstracts
Type: Oral
Session: 642. Chronic Lymphocytic Leukemia: Clinical and Epidemiological: Drugs in Development and COVID-19
Hematology Disease Topics & Pathways:
Research, Lymphoid Leukemias, adult, epidemiology, CLL, Clinical Research, Diseases, real-world evidence, Lymphoid Malignancies, Human
Monday, December 12, 2022: 5:45 PM

Andrea Visentin, MD, PhD1*, Lydia Scarfo, MD2*, Thomas Chatzikonstantinou, MD3*, Anargyros Kapetanakis4*, Christos Demosthenous5*, Georgios Karakatsoulis6*, Martin Andres, MD7*, Darko Antic, PhD8*, David Allsup, MD9*, Mónica Baile10*, Dominique Bron, MD PhD11,12, Antonella Capasso13*, Mark Catherwood, PhD14*, Rosa Collado15*, Raul Cordoba, MD, PhD16, Carolina Cuéllar-García17*, Julio Delgado, MD, PhD18,19*, Maria Dimou20, Michael Doubek, MD, PhD21, Lorenzo De Paoli, MD22*, Maria Rosaria De Paolis23*, Giovanni Del Poeta, MD24*, Maria Efstathopoulou25*, El-Ashwah Shimaa26*, Alicia Enrico27*, Lucia Farina28*, Angela Ferrari29*, Myriam Foglietta, MD30*, Moritz Furstenau, MD31, Jose A. Garcia-Marco32, Massimo Gentile, MD33*, Eva Gimeno34*, Gomes da Silva Maria35*, Odit Gutwein, MD36*, Yervand Hakobyan, PhD37*, Yair Herishanu38*, jose Angel Hernandez, MD39*, Tobias Herold, MD40, Sunil Iyengar41*, Gilad Itchaki42*, Ozren Jaksic, MD, PhD43, Ann Janssens, MD, PhD44*, Olga Kalashnikova, MD45*, Elzbieta Kalicinska46*, Arnon P. Kater, MD, PhD47, Sabina Kersting, MD, PhD48*, Jorge Labrador49,50*, Deepesh Lad, MD, DM51, Luca Laurenti, MD52*, Mark-David Levin53, Enrico Lista, MD54*, Lara Malerba55*, Roberto Marasca, MD56, Monia Marchetti57*, Juan Marquet Palomanes, MD58*, Mattias Mattsson, MD, PhD59*, Francesca Romana Mauro, MD60*, Carlota Mayor-Bastida61*, Marta Morawska, MD62*, Marina Motta, MD63*, Talha Munir, MBBS, MRCP, FRCPath, PhD64,65*, Roberta Murru66*, Ivana Milosevic67*, Fatima Miras Calvo, MD68*, Carsten Utoft Niemann, MD, PhD69, Jacopo Olivieri70*, Lorella Orsucci, MD71*, Maria Papaioannou72*, Miguel Arturo Pavlovsky73, Inga S. Piskunova74*, Barbara Pocali, MD75*, Viola Maria Popov, MD, PhD, MSc76, Francesca Maria Quaglia77*, Giulia Quaresmini78*, Doreen te Raa, MD, PhD79*, Gianluigi Reda, MD80*, Gian Matteo Rigolin81,82*, Rosa Ruchlemer, MD83*, Amit Shrestha, MD84*, Martin Šimkovič85*, Martin Špaček86*, Paolo Sportoletti, MD87*, Oana Stanca Ciocan, MD88*, Tamar Tadmor, MD89*, Elisabeth Vandenberghe, MD, PhD90*, Marzia Varettoni, MD91*, Candida Vitale92*, Ellen Van Der Spek93*, Michel Van Gelder, MD, PhD94, Ewa Wasik-Szczepanek95*, Lucrecia Yáñez, MD, PhD96*, Mohamed A Yassin, MBBS, MSC, CABM, MSC, FACP97, Marta Coscia98*, Barbara Eichhorst, MD99, Alessandro Rambaldi, MD100, Niki Stavroyianni101*, Livio Trentin1, Kostas Stamatopoulos, MD, PhD102* and Paolo Ghia, MD, PhD103

1Hematology and Clinical Immunology Unit, Department of Medicine, University of Padova, Padova, Italy
2Università Vita-salute San Raffaele and IRCC Ospedale San Raffaele, Milan, Italy
3Hematology Department and HCT Unit, George Papanicolaou Hospital, Thessaloniki, GRC
4Institute of Applied Biosciences, Centre For Research and Technology Hellas, Thessaloniki, GRC
5Hematology Department and HCT Unit, G. Papanicolaou Hospital, Thessaloniki, Gree, Thessaloniki, GRC
6Institute of Applied Biosciences, Centre for Research and Technology Hellas, Thessaloniki, Greece
7Department of Hematology and Central Hematology Laboratory, University Hospital/Inselspital Bern, University of Bern, Switzerland, Bern, Switzerland
8Clinic for hematology, Clinical Center of Serbia, Beograd, Serbia
9Centre for Atherothrombosis and Metabolic Disease, Hull York Medical School, Hull, United Kingdom
10Hospital Universitario de Salamanca/IBSAL, CIBERONC and Center for Cancer Research, Salamanca, Spain
11Dpt of Hematology, Institut Jules Bordet, ULB, 1 Rue Heger Bordet, Belgium
12Department of Hematology, Institut Jules Bordet (ULB), Brussels, Belgium
13IRCCS Ospedale San Raffaele, Milano, Italy
14Haematology Department, Belfast City Hospital, Belfast, United Kingdom
15Department of Hematology, Hospital General Universitario, Valencia, Spain
16Lymphoma Unit, Department of Hematology, Fundacion Jimenez Diaz University Hospital, Health Research Institute IIS-FJD, Madrid, Spain
17Hematology Unit Terrassa Hospital, Terrasa, Spain
18Department of Hematology, Hospital Clínic of Barcelona, Barcelona, Spain
19Hospital Clínic of Barcelona, Barcelona, Spain
201st Internal Medicine Department, Propaedeutic, Hematology Clinical Trial Unit, National and Kapodistrian University of Athens, Athens, Greece
21Department of Internal Medicine - Hematology and Oncology, University Hospital and Faculty of Medicine, Masaryk University, Brno, Czech Republic
22Division of Hematology, Department of Translational Medicine, Università del Piemonte Orientale, Novara, Italy
23UOC Ematologia PO Vito Fazzi, Lecce, Italy
24Hematology, Department of Biomedicine, University Tor Vergata Roma, Italy, Rome, Italy
25Iatriko Medical Center, Athens, Greece
26Clinical Hematology Unit, Oncology Center, Faculty of Medicine, Mansoura University, Mansoura, Egypt
27Hospital Italiano La Plata, La Plata, Argentina
28Hematology, Fondazione IRCCS Istituto Nazionale Tumori, Milan, Italy
29Ematologia, AO Arcispedale Santa Maria Nuova - IRCCS, Reggio Emilia, Italy
30SC Ematologia, AO S. Croce e Carle, Cuneo, Italy
31Department I of Internal Medicine and Center of Integrated Oncology ABCD Cologne, German CLL Study Group, Faculty of Medicine and University Hospital of Cologne, University of Cologne, Cologne, Germany, Cologne, Germany
32Hematology Department, Hospital Universitario Puerta de Hierro-Majadahonda, Majadahonda, Spain
33Hematology Unit AO Cosenza, Cosenza, Italy
34Laboratoris de Citogenètica Molecular i Citologia Hematològica, Servei de Patologia i Servei Hematologia, Hospital del Mar, Barcelona, Spain
35Division of Hematology, Instituto Português de Oncologia de Lisboa, Lisbon, Portugal
36Asaf Harophe Medical Center, Rishon Lezion, Israel
37Hematology Center, Yerevan, Armenia
38Tel-Aviv Sourasky Medical Center and Sackler School of Medicine, Tel Aviv University, Tel-Aviv, ISR
39Hospital Universitario Infanta Leonor, Madrid, Spain
40Laboratory for Leukemia Diagnostics, Department of Medicine III, Ludwig-maximilians-Universitaet (LMU), Munich, Bavaria, Germany
41Royal Marsden Hospital, London, United Kingdom
42Division of Hematology, Rabin Medical Center, Petah Tikva, and the Sackler School of Medicine, Tel-Aviv University, Petah Tikva, Israel
43Division of Hematolog, Dubrava University Hospital, Zagreb, Croatia
44Department of Hematology, Universitaire Ziekenhuizen Leuven, Leuven, Belgium
45Federal State Budgetary Educational Institution of Higher Education Academician I.P., Pavlov First St. Petersburg State Medical University of the Ministry of Healthcare of Russian Federation, St. Petersburg, RUS
46Department and Clinic of Hematology, Blood Neoplasms and Bone Marrow Transplanta, Wroclaw, Poland
47Department of Hematology, Cancer Center Amsterdam, Amsterdam University Medical Centers, University of Amsterdam, Amsterdam, Netherlands
48Department of Hematology, Haga Teaching Hospital, The Hague, Netherlands
49Hematology Department, Research Unit, Hospital Universitario de Burgos, Burgos, Spain
50Hospital Universitario de Burgos, Burgos, Burgos, Spain
51Postgraduate Institute of Medical Education and Research, Chandigarh, India
52Sezione di Ematologia, Dipartimento di Scienze Radiologiche ed Ematologiche, Università Cattolica del Sacro Cuore, Rome, Italy
53Department of Internal Medicine, Albert Schweitzer hospital, Dordrecht, Netherlands
54Hematology unit, Hospital of Trento, Trento, Italy
55Hematology and Stem Cell Transplant Center Marche Nord Hospital, Pesaro, Italy
56Dept of Medical Sciences, Section of Hematology, University of Modena and Reggio Emilia, Modena, Italy
57Division of Hematology, Hospital Antonio e Biagio and Cesare Arrigo, Alessandria, Italy
58Hematology Service, Hospital Universitario Ramón y Cajal, Madrid, 28012, Spain
59Department of Hematology and Department of Immunology, Genetics and Pathology, Uppsala University Hospital, Uppsala, Sweden
60Hematology, Department of Translational and Precision Medicine, Sapienza University, Policlinico Umberto I, Roma, Italy
61La Princesa University Hospital, Madrid, Spain
62Experimental Hemato-oncology Department, Medical University of Lublin, Lublin, Poland
63SC Ematologia, ASST Spedali Civili di Brescia, Brescia, Italy
64Department of Haematology, St James’s University Hospital, Leeds, United Kingdom
65Consultant Haematologist, St James's Hospital, Leeds, United Kingdom
66Hospital A. Businco, ARNAS “G. Brotzu”, Cagliari, CAGLIARI, Italy
67University of Novi Sad, Novi Sad, Serbia
68Hospital 12 de Octubre, Madrid, Spain
69Department of Hematology, Rigshospitalet, Copenhagen University Hospital, Copenhagen, Denmark
70Clinica Ematologica, Centro Trapianti e Terapie Cellulari "Carlo Melzi", Azienda Sanitaria Universitaria Integrata di Udine, Udine, Italy
71Division of Hematology, Azienda Ospedaliera e Universitaria Città della Salute e della Scienza, Torino, Italy
72First Department of Medicine, Aristotle University of Thessaloniki, Thessaloniki, Greece
73FUNDALEU, Clinical research center Buenos Aires, Buenos Aires, Argentina
74Consultative Hematology Department with a Day Hospital for Intensive High-Dose Chemotherapy, National Research Center for Hematology, Moscow, Russian Federation
75Division of Hematology and Stem Cell Transplantation Unit, Cardarelli Hospital, Naples, Italy
76Hematology, Colentina Clinical Hospital, Bucharest, Arges, Romania
77Department of Medicine, Section of Hematology, University of Verona, Verona, Italy
78Hematology, ASST Papa Giovanni XXIII, Bergamo, Italy
79Department of hematology, Gelderse Vallei, Ede, Netherlands
80Hematology unit, Hematology Unit, Foundation IRCCS Ca’ Granda Ospedale Maggiore Policlinico of Milan, Milan, Italy
81St. Anna University Hospital, Ferrara, Italy
82Hematology section, Department of Medical Sciences, Azienda Ospedaliera- Universitaria, Arcispedale S. Anna, University of Ferrara, Ferrara, Italy
83Department of Hematology, Shaare-Zedek Medical Center, affiliated with the Hebrew University Medical School, Jerusalem, Israel
84Civil Service Hospital, Kathmandu, Nepal
854th Department of Internal Medicine – Haematology, Faculty of Medicine in Hradec Králové, University Hospital and Charles University in Prague, Hradec Kralove, Czech Republic
861st Department of Medicine - Hematology, First Faculty of Medicine, Charles University and General Hospital in Prague, Prague, Czech Republic
87Department of Medicine, Division of Hematology and Clinical Immunology, University of Perugia, Perugia, Italy
88Coltea Clinical Hospital, Bucharest, Romania
89Bnai Zion Medical Center, Haifa, Israel
90Haematology Department, St. James Hospital, Dublin, Ireland
91Division of Hematology Fondazione IRCCS Policlinico San Matteo, Pavia, Italy
92Division of Hematology, A.O.U. Cittàdella Salute e dellaScienza di Torino and Department of Molecular Biotechnology and Health Sciences, University of Turin, Turin, TX, Italy
93Rijnstate hospital, department of internal medicine Arnhem, Arnhem, Netherlands
94Department of Hematology, University Hospital Maastricht, Maastricht, Netherlands
95Dept. Hematooncology and Bone Marrow Transplantation Medical University in Lublin, Lublin, Poland
96Hematology Department, Hospital Universitario Marqués de Valdecilla, Santander, Spain
97Department of Medical Oncology/ Hematology Section, National Centre For Cancer Care & Research, Doha, Qatar
98Division of Hematology, A.O.U. Cittàdella Salute e dellaScienza di Torino and Department of Molecular Biotechnology and Health Sciences, University of Turin, Turin, Italy
99Department I of Internal Medicine, Center for Integrated Oncology Aachen Bonn Cologne Duesseldorf, German CLL Study Group, University of Cologne, Cologne, Germany
100University of Milan, Bergamo, Italy
101Hematology Department and HCT Unit, G. Papanicolaou Hospital, Thessaloniki, Greece
102Institute of Applied Biosciences, Centre For Research and Technology Hellas, Thessaloniki, Greece
103Universita' Vita-Salute San Raffaele C.F. 97187560152, Milano, MI, Italy

BACKGROUND. Infection by SARS-CoV2 remains a worldwide health burden. Previous studies by the ERIC (European Research Initiative on CLL) showed that patients with chronic lymphocytic leukemia (CLL) have a very-high risk of severe Coronavirus disease 19 (COVID19). In particular, age, CLL-directed treatment, and cardiac failure were identified as significant risk factors of overall survival (OS). Since the beginning of 2020 different treatment strategies have been used to fight COVID19 and different SARS-CoV2 variants alternated during the pandemic, however very few studies analyzed their impact on patients with CLL.

AIMS. The aims of this study were to investigate different manifestations, treatments and outcome of COVID19 in patients with CLL/SLL (small lymphocytic lymphoma), and MBL (monoclonal B-cell lymphocytosis).

METHODS. This is a retrospective international multicenter ERIC study from Jan 2020 till May 2022. CLL diagnosis, COVID-19 management, review of medical history, and assessment of patient status were performed by local investigators following international guidelines. Ninety institutions participated in the study. Statistical analyses were conducted using R software. During the pandemic we identified 4 phases: 1st Jan 2020 - Jun 2020, 2nd Jul 2020 - Feb 2021, 3rd Mar 2021 - Dec 2021 and 4th Jan 2022 - May 2022.

RESULTS. We gathered data from 1540 patients (93.8% CLL, 4.1% SLL and 2.1% MBL), 65% males, the median age at COVID19 was 69 years, median CIRS score was 4 (IQR 2-7), 49.6% were treated in the last 12 months before COVID19, 38.8% was on treatment at COVID19 onset (BTK inhibitor-based 51.1%, BCL2 inhibitor-based 20.7%, chemo/chemoimmunotherapy 21.5%, 6.7% others). Overall, 34.4% of patients was managed at home, 49.9% needed hospitalization and 15.7% was admitted to the intensive care unit (ICU). After a median follow-up of 2.7 months, the infection was resolved in 1124/1540 (73%) cases, while 23% died and 3.6% were still under medical observation.

Distribution of patients among time is shown in Fig. 1A. Three hundred and four (19.8%) patients were infected during the 1st, 737 (48%) during the 2nd, 137 (8.9%) during the 3rd and 357 (23.3%) during the last 4th phase.

Comparing the features of patients infected in different phases, age at COVID19 and distribution of biological markers were similar, but more patients in the latter phases suffered from arrhythmias (8.2% vs 10.5% vs 16.1% vs 14.2%, p=0.01), chronic renal disease (3.9% vs 5.9% vs 8.9% and 11.1%, p=0.003) and other malignancies (0.3% vs 1.8% vs 2.2% vs 3.6%, p=0.04). Vaccinated patients (0% vs 0.4% vs 45.7% vs 89.1%, p<0.001) and those treated for CLL in the last 12 months (44.1% vs 44.1% vs 55.7% vs 66.1%, p<0.001) were also more common in the last phases.

COVID19 signs and symptoms differed between early and late phases, with less fever (p<0.001) and dyspnea (p=0.028) but more fatigue (p<0.001), cough (p<0.001), headache (p<0.001), anosmia/ageusia (p<0.001) and myalgia/arthralgia (p<0.001) in the later phases.

COVID19 management also changed over time, with less patients receiving a SARS-CoV2 therapy (87.6% vs 74.7% vs 78.1% vs 67.9%, p<0.001). In particular, hydroxychloroquine, azithromycin, steroids and anti-IL6/IL6R were more commonly used in the first 2 phases while antiviral and monoclonal antibodies (mAb) were mainly employed in the last 2 phases. Less patients were hospitalized (84.5% vs 67.3% vs 60.3% vs 45.8%, p<0.001), needed ICU admission (20.6% vs 17.2% vs 13.3% vs 8.1%, p<0.001) or died (29.8% vs 25.5% vs 21.8% vs 15.8%, p=0.002) through these phases. These improvements in patients’ management led to an increase of OS, with 2-month OS of 70%, 74%, 81% and 83% for patients diagnosed during the 1st, 2nd,3rd and 4th phase (p=0.0015, Fig. 1B).

CONCLUSION. We analyzed one of the largest series of patients with CLL infected by SARS-CoV2 over more than 2 years of COVID19 pandemic. Patients infected during the most recent phases, though carrying a higher comorbidity burden, were less frequently hospitalized, only rarely needed ICU admission and died due to the SARS-CoV2 infection in a lower proportion compared to initial phases. The improvement in COVID-19 management with effective antiviral drugs, mAb and the high rate of vaccination together with the change in SARS-CoV2 variants over time may have played an important role in this outcome.

AV, LS, TC, AK, CD and GK equally contributed. KS and PG are both last authors.

Disclosures: Visentin: Janssen, Abbvie, CSL Behring: Consultancy, Membership on an entity's Board of Directors or advisory committees, Speakers Bureau; Beigene: Membership on an entity's Board of Directors or advisory committees, Research Funding; AstraZeneca: Consultancy; Gilead: Consultancy; Takeda: Consultancy, Membership on an entity's Board of Directors or advisory committees, Research Funding. Scarfo: AbbVie, AstraZeneca, Janssen, Beigene, Lilly: Honoraria; BeiGene, Janssen: Other: Travel Grant; Octapharma: Speakers Bureau. Andres: Abbvie: Membership on an entity's Board of Directors or advisory committees, Other: Travel Support; AstraZeneca: Membership on an entity's Board of Directors or advisory committees, Other: Travel Support; Janssen-Cilag: Membership on an entity's Board of Directors or advisory committees, Other: Travel Support. Cordoba: BeiGene: Consultancy; Janssen: Consultancy, Honoraria, Speakers Bureau; Incyte: Consultancy; GenMab: Consultancy; Takeda: Consultancy; Kite: Consultancy, Speakers Bureau; Pfizer: Research Funding; Bristol Myers Squibb: Consultancy, Honoraria; Celgene: Honoraria; Gilead: Honoraria; Lilly: Consultancy; AstraZeneca: Consultancy, Honoraria, Speakers Bureau; AbbVie: Consultancy, Honoraria, Speakers Bureau; Roche: Consultancy, Honoraria, Speakers Bureau. Doubek: AbbVie: Honoraria; AOP Orphan: Consultancy, Research Funding; AstraZeneca: Consultancy, Honoraria, Research Funding; Janssen: Honoraria. Hernandez: Janssen: Membership on an entity's Board of Directors or advisory committees, Speakers Bureau; Roche: Membership on an entity's Board of Directors or advisory committees, Speakers Bureau; Abbvie: Membership on an entity's Board of Directors or advisory committees, Speakers Bureau; AstraZeneca: Membership on an entity's Board of Directors or advisory committees, Speakers Bureau; Beigene: Membership on an entity's Board of Directors or advisory committees; Lilly: Membership on an entity's Board of Directors or advisory committees; Gilead: Membership on an entity's Board of Directors or advisory committees, Speakers Bureau; BMS/Celgene: Membership on an entity's Board of Directors or advisory committees, Speakers Bureau; Amgen: Membership on an entity's Board of Directors or advisory committees, Speakers Bureau; Takeda: Membership on an entity's Board of Directors or advisory committees, Speakers Bureau; Jazz: Membership on an entity's Board of Directors or advisory committees; Rovi: Membership on an entity's Board of Directors or advisory committees; Incyte: Membership on an entity's Board of Directors or advisory committees. Iyengar: Janssen: Speakers Bureau; AbbVie: Other: conference support; Takeda: Membership on an entity's Board of Directors or advisory committees, Other: conference support, Speakers Bureau; Lilly: Membership on an entity's Board of Directors or advisory committees; Beigene: Membership on an entity's Board of Directors or advisory committees; Kite Gilead: Membership on an entity's Board of Directors or advisory committees. Itchaki: AstraZeneca: Consultancy; Janssen: Consultancy; Abbvie: Consultancy. Jaksic: Astra Zeneca: Consultancy, Speakers Bureau; Abbvie: Speakers Bureau; Johnson and Johnson: Speakers Bureau. Janssens: Genmab: Current Employment; Abbvie: Consultancy, Other: Travel Grants, Speakers Bureau; Amgen: Consultancy, Other: travel grants, Speakers Bureau; Astra-Zeneca: Consultancy, Speakers Bureau; Beigene: Consultancy, Speakers Bureau; Janssen: Consultancy, Speakers Bureau; Incyte: Consultancy, Speakers Bureau; Novartis: Consultancy, Speakers Bureau; Sobi: Consultancy, Speakers Bureau; Sanofi Genzyme: Consultancy, Speakers Bureau; Roche: Consultancy; Celgene: Other: travel grants. Kater: BMS: Membership on an entity's Board of Directors or advisory committees, Research Funding; Janssen: Membership on an entity's Board of Directors or advisory committees, Other: speakers fee, Patents & Royalties: pending, Research Funding; Roche/genentech: Membership on an entity's Board of Directors or advisory committees; LAVA: Membership on an entity's Board of Directors or advisory committees, Patents & Royalties: pending; Astra Zeneca: Membership on an entity's Board of Directors or advisory committees, Other: speakers fee, Research Funding; Abbvie: Membership on an entity's Board of Directors or advisory committees, Other: speakers fee, Research Funding. Levin: AbbVie, Roche and Janssen: Other: Travel expenses. Mauro: Janssen, Astra Zeneca, Beigene: Consultancy, Honoraria; Abbvie, Takeda: Honoraria, Research Funding, Speakers Bureau. Munir: Janssen, AstraZeneca, Alexion, Sobi, Novartis, Roche, Abbvie, Gilead: Honoraria; Janssen, AstraZeneca, Alexion, Abbvie, Novartis, Roche: Membership on an entity's Board of Directors or advisory committees. Murru: Janssen: Research Funding; Janssen, Abbvie, Astra Zeneca: Honoraria, Other: travel. Niemann: Takeda: Consultancy; CSL Behring: Consultancy; Octapharma: Consultancy, Research Funding; Janssen: Consultancy; AstraZeneca: Consultancy, Research Funding; Abbvie: Consultancy, Research Funding; Beigene: Consultancy; Genmab: Consultancy. Pavlovsky: AstraZeneca: Other; AbbVie: Other: Conference; AbbVie: Membership on an entity's Board of Directors or advisory committees; Janssen: Membership on an entity's Board of Directors or advisory committees; Janssen: Other: Conference; Raffo: Membership on an entity's Board of Directors or advisory committees; AstraZeneca: Membership on an entity's Board of Directors or advisory committees. Reda: Janssen, Abbive, Astra Zeneca, Beigene: Consultancy. Rigolin: Abbvie: Honoraria; AstraZeneca: Honoraria; Janssen: Honoraria; Gilead: Honoraria, Research Funding. Šimkovič: Gilead: Current holder of stock options in a privately-held company; AstraZeneca: Consultancy, Current holder of stock options in a privately-held company, Honoraria, Membership on an entity's Board of Directors or advisory committees, Other: Travel, Accommodations, Expenses; BeiGene: Current holder of stock options in a privately-held company; AbbVie: Consultancy, Current holder of stock options in a privately-held company, Honoraria, Membership on an entity's Board of Directors or advisory committees, Other: Travel, Accommodations, Expenses; Janssen-Cilag: Consultancy, Honoraria, Membership on an entity's Board of Directors or advisory committees, Other: Travel, Accommodations, Expenses; J&J: Current holder of stock options in a privately-held company; Baxter: Current holder of stock options in a privately-held company; Novartis: Current holder of stock options in a privately-held company; Abbot: Current holder of stock options in a privately-held company; Sanofi: Current holder of stock options in a privately-held company. Tadmor: Janssen: Research Funding; AbbVie, Roche, Novartis, Sanofi, Takeda, Janssen, Pfizer: Consultancy, Honoraria, Speakers Bureau. Varettoni: ABBVIE: Honoraria, Membership on an entity's Board of Directors or advisory committees, Other: travel expenses; ASTRAZENECA: Membership on an entity's Board of Directors or advisory committees; BEIGENE: Membership on an entity's Board of Directors or advisory committees, Other: travel expenses; JANNSEN: Membership on an entity's Board of Directors or advisory committees, Other: travel expenses. Eichhorst: Janssen, AbbVie, Lilly, AstraZeneca, BeiGene, MSD: Consultancy; Janssen, Roche, AbbVie, BeiGene, AstraZeneca, MSD: Speakers Bureau; Beigene: Other: Travel Support; Janssen, Roche, AbbVie, BeiGene, AstraZeneca: Research Funding. Rambaldi: Roche: Honoraria; Incyte: Honoraria; Novartis: Honoraria; Kite-Gilead: Honoraria; Jazz: Honoraria; ABBVIE: Honoraria; Astellas: Honoraria; Pfizer: Honoraria; Amgen: Honoraria; Janssen: Honoraria; Celgene-BMS: Honoraria; Omeros: Honoraria. Stamatopoulos: AbbVie: Research Funding. Ghia: BMS: Consultancy, Honoraria; Janssen: Consultancy, Honoraria, Research Funding; BeiGene: Consultancy, Honoraria; MSD: Consultancy, Honoraria; Roche: Consultancy, Honoraria; AstraZeneca: Consultancy, Honoraria, Research Funding; Lilly/Loxo: Consultancy, Honoraria; AbbVie: Consultancy, Honoraria, Research Funding.

<< Previous Abstract | Next Abstract
*signifies non-member of ASH